TB-500 (Thymosin Beta-4): what the published research shows

TB-500 is the synthetic peptide corresponding to the 17–23 fragment of thymosin beta-4 (Tβ4), a naturally occurring actin-binding protein. It is also referred to as the thymosin beta-4 17–23 fragment, Tβ4(17–23), and Ac-SDKP-related fragment in some of the literature. The evidence block provided for this page does not supply a sequence, molecular formula, or molecular weight, so none are stated here. The work described centres on the peptide's interaction with the actin cytoskeleton and its downstream effects on vascular function and inflammatory signalling.

The research record for TB-500 is dominated by preclinical work. The single clinical entry in the evidence block is a Phase 1/2 trial in adults with stable atherosclerotic cardiovascular disease (ASCVD), which is described as evaluating safety and tolerability versus placebo, with exploratory endpoints assessing vascular function and inflammation biomarkers [1]. That is the extent of the human data available in the evidence provided. Everything else discussed below is either animal-only or in vitro, and is labelled as such.

Research Studies

TB-500 and vascular function biomarkers in stable ASCVD

The only clinical study in the evidence block is a Phase 1/2 trial of TB-500 (Thymosin Beta-4) versus placebo in adults with stable ASCVD [1]. The primary objective is safety and tolerability. Exploratory endpoints assess vascular function and inflammation biomarkers [1]. Because the record describes exploratory endpoints, any biomarker signal reported from this trial would be hypothesis-generating rather than confirmatory. The evidence block does not provide enrolment numbers, dose, duration, or results, so none are reported here.

This is the only human study cited on this page. No efficacy conclusion in a human population can be drawn from a single Phase 1/2 record with exploratory endpoints.

TB-500 and the actin cytoskeleton in vitro

Thymosin beta-4 is an actin-sequestering protein, and the 17–23 fragment is the region most closely associated with that activity. In vitro work has examined how the fragment interacts with actin monomers and influences filament dynamics. The evidence block does not provide a specific in vitro study for TB-500, so no numerical values, cell lines, or assay results are stated here. The mechanistic rationale for studying the fragment in vascular and inflammatory contexts rests on this actin-binding property, but the evidence block does not contain a citation that quantifies it.

TB-500 and inflammation biomarkers

Inflammation biomarkers are listed as exploratory endpoints in the ASCVD trial [1]. The evidence block does not name which biomarkers, nor does it report any measured values. No claim is made here about the direction or magnitude of any inflammatory marker in any population, because the evidence does not support one.

TB-500 and vascular function

Vascular function is the second exploratory endpoint category in the ASCVD trial [1]. As with the inflammation biomarkers, the evidence block does not specify the measurement method or report results. The trial is described as evaluating safety and tolerability first; vascular function is exploratory. No statement is made here about whether vascular function changed in the trial participants.

TB-500 in animal models

The evidence block does not contain a specific animal study of TB-500. General statements about thymosin beta-4 in animal models of cardiac or vascular injury exist in the wider literature, but they are not cited in the evidence provided for this page, so they are not described here. Any reader who encounters such claims elsewhere should check whether the study was in animals or in humans, and whether the compound was full-length thymosin beta-4 or the 17–23 fragment.

TB-500 and the 17–23 fragment versus full-length thymosin beta-4

The distinction matters. Full-length thymosin beta-4 is a 43-amino-acid protein. TB-500 is described in the evidence block as a 17–23 fragment [1]. The two are not interchangeable in a research context, and a study of one does not automatically apply to the other. The evidence block provides only the fragment study, so no comparison table between the two is possible from the evidence given.

TB-500 and safety reporting in the clinical record

The ASCVD trial is described as evaluating safety and tolerability of TB-500 versus placebo [1]. The evidence block does not report adverse event rates, serious adverse events, or discontinuations. No safety conclusion is drawn here beyond the fact that safety and tolerability are the stated primary objective of that trial.

TB-500 and study population: stable ASCVD

The population in the clinical record is adults with stable atherosclerotic cardiovascular disease [1]. This is a specific population. Findings from that population would not automatically generalise to healthy adults, to other cardiovascular conditions, or to any other group. The evidence block does not contain studies in other populations.

What the evidence does and does not show

Limitations of the current record

The clinical record in the evidence block is a single Phase 1/2 trial with safety and tolerability as the primary objective and vascular function and inflammation biomarkers as exploratory endpoints [1]. Exploratory endpoints are not designed to confirm efficacy. The evidence block does not report enrolment, dose, duration, or results, so the trial cannot be used here to support any claim about what TB-500 does in humans.

The preclinical record for TB-500 is not represented in the evidence block at all. That is a limitation of this page, not a statement that no preclinical work exists. It means that any mechanistic statement about the 17–23 fragment on this page is limited to the general actin-binding character of thymosin beta-4, without a specific citation from the evidence provided.

Finally, the fragment-versus-full-length distinction is a recurring source of confusion. The evidence block describes TB-500 as a 17–23 fragment [1]. Research on full-length thymosin beta-4 should not be read as research on TB-500 without checking the identity of the compound used.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — ClinicalTrials.gov